MedTrace Logo

Clinical and Molecular Correlates of Response to First Line Treatment in Lichen Planus

NCT05330572 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2026-05-22

No results posted yet for this study

Summary

Lichen planus is a common inflammatory (swelling and pain of tissue) disease in the general population that affects mostly the mouth although skin and genital areas can also be affected. It can cause considerable discomfort during activities such as eating, talking and tooth brushing and may impair sexual function with an overall deleterious impact on quality of life. There is also increased evidence of cancer in a subtype of lichen planus. Therefore, treatment is essential in these patients to control the symptoms and improve the quality of life.

Locally applied steroids are the first line medicines used in the treatment of patients with lichen planus. This medicine can only control the symptoms, but cannot cure the disease. In addition, this treatment cannot be effective in all patients with lichen planus. This may be attributed to differences in host factors, mouth bacteria and individual host responses to bacteria. The exact cause of this disease is also unknown. New studies have shown changes in the balance of mouth bacteria and host responses to bacteria in patients with lichen planus. So the main purpose of our study is to identify clinical(age, gender, related medical conditions, oral health and the presence of deleterious habits like smoking and alcohol consumption), molecular(analysis of oral microbes and immune markers) and histological factors (change within tissue) associated with poor response in lichen planus patients undergoing treatment with locally applied steroid medicines. Overall, knowledge of these factors associated with disease progression is sparse, which limits progress in the realm of development of novel and personalised treatment strategies. In this study, we explore the individual and combined role of different markers in lichen planus for improving diagnosis, predicting disease progression and treatment effectiveness.

Conditions

  • Lichen Planus, Oral
  • Lichen Planus of Vulva

Interventions

OTHER

No interventions were administered to the patients as a part of this study.

No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.

Sponsors & Collaborators

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Dr Karolin Hijazi · University of Aberdeen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05330572 on ClinicalTrials.gov